Cite

    Halim, N. et al. (n.d.). Topic: AS08-Treatment/AS08a-Current treatment options - Higher risk MDS: SINGLE-CENTER EXPERIENCE OF AZACITIDINE-VENETOCLAX IN SECONDARY ACUTE MYELOID LEUKEMIA (AML), ARISING FROM MYELODYSPLASTIC SYNDROME (MDS), MYELOPROLIFERATIVE NEOPLASM (MPN) OR MDS/MPN OVERLAP. Leukemia research. p. . [Online].